• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Doximity (DOCS) Is Up 5.5% After AI Optimism Lifts Enterprise SaaS Peers' Results What's Changed

    Simply Wall St·08/29/2026 18:18:11
    Listen to the news
    • In recent days, enterprise software and SaaS stocks rallied after several peers reported stronger-than-expected quarterly results, highlighting how generative AI is enhancing, rather than replacing, existing platforms.
    • For Doximity, this sector-wide optimism around AI’s role in expanding product capabilities and monetization has become an important sentiment driver for its business outlook.
    • Against this backdrop of AI-fueled enthusiasm in enterprise software, we’ll examine how this optimism may influence Doximity’s existing investment narrative.

    Find 44 companies with promising cash flow potential yet trading below their fair value.

    Doximity Investment Narrative Recap

    To own Doximity, you need to believe it can turn its physician network and AI workflow tools into durable, high quality earnings, even as growth moderates and competition intensifies. The recent AI driven rally in SaaS improves sentiment but does not materially change the near term picture: the key catalyst remains broader adoption and eventual monetization of Scribe and other AI tools, while the biggest risk is that generous free access and higher AI costs weigh on margins longer than expected.

    Against this AI optimism, the May 13 partnership with Aledade stands out. By embedding Doximity’s Clinical AI Suite directly into Aledade Assist, Doximity is pushing its tools closer to the point of care, which may reinforce its role as a daily workflow utility for clinicians. That ties directly into the main catalyst of deeper AI driven engagement, but it also raises the stakes if AI investments outpace near term revenue contribution.

    Yet even with AI excitement, investors should be aware of how heavier AI spending and rising competition could still...

    Read the full narrative on Doximity (it's free!)

    Doximity’s narrative projects $793.7 million revenue and $198.5 million earnings by 2029. This requires 6.6% yearly revenue growth and an earnings increase of about $31.5 million from $167.0 million today.

    Uncover how Doximity's forecasts yield a $29.78 fair value, a 11% upside to its current price.

    Exploring Other Perspectives

    DOCS 1-Year Stock Price Chart
    DOCS 1-Year Stock Price Chart

    While the consensus expects steady progress, the lowest analysts were assuming revenue of about US$733.8 million and earnings of roughly US$166.9 million by 2029, which bakes in much more caution about AI costs, competition and margins than the latest AI driven rally might suggest, so it is worth weighing how this news could shift those more bearish assumptions before you decide which narrative you find more convincing.

    Explore 5 other fair value estimates on Doximity - why the stock might be worth as much as 35% more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Looking For Alternative Opportunities?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.